Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treatment-naïve (TN) CLL. Per protocol, TN patients were at least 65 years old or had a del(17p)/TP53 mutation. Duvelisib was administered twice daily (BID) in 28-day cycles at doses of 8-75 mg in RR patients (n = 55) and 25 mg in TN patients (n = 18.) Diarrhea was the most common nonhematologic AE (TN 78%, RR 47%); transaminase elevations the most frequent lab-abnormality AE (TN 33.3%, RR 30.9%); and neutropenia the most common ≥grade 3 AE (RR 44%, TN 33%). The overall response rates were 56.4% for RR patients (1.8% CR, 54.5% PR) and 83.3% for TN patients (all PRs); median response duration was 21.0 months in RR patients but was not reached for TN patients. Based upon phase 1 efficacy, pharmacodynamics, and safety, duvelisib 25 mg BID was selected for further investigation in a phase 3 study in RR CLL/SLL.
macrophages from the immunosuppressive M2-like phenotype to the inflammatory, antitumor M1-like phenotype.
14 Thus, there are at least three different mechanisms through which dual inhibition of PI3K-δ and -γ isoforms could be active against lymphoid malignancies, including CLL: blockade of cell autonomous mitogenic and survival signaling, disruption of supportive tumor microenvironment juxtacrine interactions, and activation of anti-lymphoma immune responses. Accordingly, duvelisib may provide greater benefit through its dual inhibition of PI3K-δ and -γ than one PI3K isoform alone. 15 Dose escalation, maximum tolerated dose (MTD) determination, and safety for the entire enrolled phase 1 study population are described in a separate publication. 16 Here we report on the efficacy, safety, and pharmacodynamics of duvelisib in patients with relapsed/ refractory (RR) CLL/SLL and treatment-naïve (TN) CLL enrolled in expansion cohorts of the first clinical study of duvelisib in hematologic malignancies. These data support the ongoing investigation of duvelisib for CLL/SLL in a phase 3 trial.
| Patients and methods

| Study design and treatment
Study IPI-145-02 was a phase 1, open-label, dose-escalation and cohort expansion study in 210 patients with advanced hematologic malignancies. 15 Duvelisib was administered as oral capsules twice daily (BID), continuously in 28-day cycles until disease progression or unacceptable toxicity. Dose interruptions and reductions (up to 2)
were allowed. Clinic visits occurred weekly during the first three cycles, biweekly during cycles 4 (C4) and C5, monthly during C6-19, and every three cycles thereafter. Within the broader phase 1 study population, two CLL populations were examined in expansion cohorts:
55 patients with RR CLL/SLL were enrolled during dose escalation or sequentially (nonrandomized) into duvelisib 25 or 75 mg BID expansion cohorts depending upon cohort availability, and 18 patients with TN CLL received 25 mg BID. Peripheral blood and bone marrow samples were submitted at screening for central laboratory biomarker analysis, including del17p, TP53 mutation, and IGHV mutational status.
All patients provided signed informed consent. The protocol was approved by site Institutional Review Boards, and the study was conducted according to local and federal regulations and the Declaration of Helsinki.
| Key enrollment criteria
Eligible patients were required to have a life expectancy >3 months, an ECOG score of 0-2, adequate hepatic (aspartate aminotransferase Efficacy was assessed by overall response rate (ORR; CR + PR), time to response, lesion response (≥50% decrease from baseline in the sum of the product of diameters), duration of response (DOR;
months from first response to progressive disease or death), progression-free survival (PFS; months from first dose to either progressive disease or death), and overall survival (OS; months from first dose to death).
| Safety methods
Adverse events (AEs), blood chemistry, and hematology laboratory parameters were monitored at all clinic visits and summarized for all patients who received at least one dose of duvelisib. AE severity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.
| Pharmacodynamic methods
Using serum collected from iNHL or CLL patients, multiplex panels of cytokines, chemokines, and matrix metalloproteinases (74 total analytes) associated with the B-cell malignancy tumor microenvironment were evaluated using Luminex xMAP technology (Luminex, Austin, TX). The PD analysis set consisted of patients with iNHL and CLL with a C1D1 predose sample and at least one other sample (C1D8, C2D1, C3D1, or C5D1).
2 | RESULTS 2.1 | Demographic and baseline characteristics, disposition, and treatment The median age of RR patients was 66 years (range 42-82); most were male (76%), white (89%), and had a diagnosis of CLL (91%).
Nearly all had an ECOG performance status of 0 (24%) or 1 (71%) ( Abbreviations: BID, twice daily; BTKi, Bruton's tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; ECOG, Eastern Cooperative Oncology Group; IGHV, immunoglobulin heavy chain variable; NA, not applicable; RR, relapsed/refractory; SLL, small lymphocytic lymphoma; TN, treatment-naïve. a Baseline disease stage not reported for 1 patient on duvelisib 25 mg BID; the incidence is based upon patients with available data. b Bulky disease information at baseline not reported for 4 patients at 75 mg BID, and 4 patients across all doses for RR; the incidence is based upon patients with available data. c Baseline mutation status not reported for 2 patients at 25 mg BID, 3 patients at 75 mg BID, and 5 patients across all doses for RR. For TN, 1 patient had no mutation status reported at baseline. The incidence is based upon patients with available data. d Baseline IGHV mutation status was not available for 3 patients at 25 mg BID, 8 patients at 75 mg BID, and 11 patients across all doses for RR-CLL/SLL, nor for 1 patient with TN-CLL. The incidence is based upon patients with available data e Baseline mutation status was not available for 9 patients at 25 mg BID, 10 patients at 75 mg BID, and 20 patients across all doses for RR-CLL/SLL, nor for 2 patients with TN-CLL. The incidence is based upon patients with available data.
were neutropenia (43.6%) and thrombocytopenia (18.1%) and did not result in treatment discontinuation. Diarrhea (47.3%) was the most frequent nonhematologic AE, but resulted in only two treatment discontinuations. Severe diarrhea (9.1%) and colitis (5.5%) were reported less frequently, and some cases overlapped. These events were man- Twenty patients discontinued duvelisib due to AEs. Pneumonitis (4 patients), pneumonia, stomatitis, diarrhea, and colitis (all 2 patients)
were the only AEs that led to treatment discontinuation in more than one patient. Fatal AEs occurred in nine patients. Four were due to disease progression and three were AEs considered unrelated to study Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; URTI, upper respiratory tract infection. Notes: Patients are counted once within each system organ class and preferred term. Percentages are based on the number of patients in each dose group for the All-Treated Analysis Set. Patients with an event in more than 1 grade are counted only once at the maximum grade within each system organ class, and within each preferred term. a AEs were coded using the Medical Dictionary of Regulatory Activities (MedDRA) version 16.1, and were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. b Includes the preferred terns of pneumonia (n = 13), lung infection (n = 2), lung infiltration (n = 1), pneumonia Pseudomonas aeruginosa (n = 1), Bronchopulmonary aspergillosis (n = 1), pneumonia aspiration (n = 1), pneumonia Escherichia (n = 1), and pneumonia respiratory syncytial viral (n = 1).
treatment: one each due to pneumonia Pseudomonas aeruginosa sepsis, cardiac arrest/respiratory failure, and sepsis. Two deaths were considered related to treatment by the investigator. One patient receiving 25 mg BID discontinued duvelisib after 158 days due to disease progression and died 21 days later due to respiratory syncytial viral pneumonia. Another patient receiving 75 mg BID died due to metabolic acidosis in the setting of sepsis and renal failure after 70 days of duvelisib.
| Treatment-naïve CLL
The most frequent treatment-emergent AEs were similar to those observed in RR patients (Table 2B ). Neutropenia was the most common ≥ grade 3 AE (6, 33.4%). The incidences of all-grade (14, 77.8%) and severe diarrhea events (4, 22.2%) were higher in TN patients, but manageable with dose modifications and resulted in only one treatment discontinuation. Median times to any-grade or severe diarrhea (grade 3, no grade 4) events were 2.6 and 9.7 months, respectively.
AST/ALT elevations occurred in 6 (33.3%) patients, three of whom experienced grade-3 events, resulting in one treatment discontinuation. Similar to the RR population, the most common infectious AEs in TN patients were pneumonia and URTI, in 4 (22.2%) patients each.
Other than oral Candida and a Grade 1 herpes zoster event in one subject each, no opportunistic infections were reported. Colitis was reported in three patients, with onset at 7.2, 12.4, and 17 months; two of these patients had grade 3 events and discontinued treatment. Figure 1 A). The median time to response was 1.87 months (range 1.6-16.6). A nondose-dependent lymphocytosis following duvelisib initiation was noted in 75% of patients with absolute lymphocyte counts (ALC) returning to baseline around C5D1 (Supporting Information Figure 2 A). Stable disease (SD) was the best response in 19 (34.5%) patients, 6 of whom (32%) achieved a nodal response and met at least one group B criterion but had persistent treatment-related lymphocytosis; 2 (3.6%) patients did not achieve any response. In patients with TP53 mutation or 17p deletion, the ORR was 46.4% (13/28), including one Across all doses, median PFS was 15.7 months (Figure 1 ). PFS events included 23 disease progressions and three deaths. The Table 3 ). The absence of a postbaseline assessment precluded response determination in one patient, and the remaining two patients (11.1%) had SD as their best response.
The median time to response was 3.71 months (range 1.7-8.3). Nodal response (≥50% reduction in adenopathy) occurred in 87.5% (14/16) of patients with radiologically assessed baseline disease (Supporting Information Figure 1B ). Similar to RR CLL/SLL, lymphocytosis was observed shortly after duvelisib initiation in 70.6% of TN patients, with return to baseline ALC for the population occurring around C3D1 (Supporting Information Figure 2B ).
The median DOR was not reached, with estimated 6-and 12-month probabilities of remaining in response of 100% and 87.5%, respectively. The median PFS and OS were also not reached, with estimated probabilities of remaining progression-free and surviving at 12 months of 94% and 100%, respectively.
| Duvelisib pharmacodynamics in CLL
Chemokines, cytokines, and serum factors reflective of CLL tumor cells, the immune system, and the tumor microenvironment were evaluated in an exploratory analysis by collecting blood samples at baseline and at various timepoints during cycles 1-3. Supporting
Information Table 1 lists all of the chemokines, cytokines, and serum factors evaluated; 13 of the 74 analytes tested decreased significantly from baseline at cycle 1 Day 8 (C1D8) and displayed ≥50% median 
Abbreviations: BID, twice daily; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma. Notes: The Clopper-Pearson confidence interval is presented. Patients with no post-baseline response assessment are represented as having an 'unknown' response. Percentages are based on the number of patients in each dose group. a Among RR patients with stable disease, 6/19 (32%) had a lymph node response and persistent lymphocytosis, meeting the criteria for partial response for agents causing increased peripheral blood lymphocytes {Cheson, 2012 #2743}.
FIGURE 1 Progression-free survival and overall survival in patients with relapsed/refractory CLL/SLL change: CCL1, CCL3, CCL4, CCL17, CCL22, CXCL10, CXCL13, IL-6, IL-10, IL-12p40, MMP-9, MMP-12, and TNFα (Supporting Information Figure 3A ) with P value <.0018 after Bonferroni correction for the 74 multiple comparisons. All 13 analytes were elevated at baseline in the serum from RR patients compared to healthy donors (n = 33). All but IL-6 were statistically significantly decreased at C2D1 and C3D1 compared to baseline. After 8 days of duvelisib, seven of these analytes were no longer significantly higher than healthy donor samples (data not shown).
Pharmacodynamic data were collected from 17 TN patients (94%); 10 of the 74 serum analytes tested had decreased significantly at C1D8 with ≥50% median change: CCL3, CCL4, CCL17, CCL22, CXCL10, CXCL13, IL-10, IL-12p40, MMP-9, and TNFα (Supporting Information Figure 3B ) with P value <.0018 after Bonferroni correction for the 74 multiple comparisons. All analytes except CXCL10 also exhibited significant decreases at C2D1 and C3D1. Only IL-6 changed significantly at C2D1 or C3D1 but not at C1D8; 9 of these 10 analytes (except CXCL10) were elevated at baseline in TN serum compared with healthy donors (n = 33). After 8 days of duvelisib, levels of five of the analytes elevated at baseline were no longer significantly higher than healthy donor samples (data not shown).
| DISCUSSION
Here we present the first demonstration of the anti-leukemic activity and safety of duvelisib in patients with CLL/SLL. Data were collected within a broader phase 1 study in patients with multiple advanced hematologic malignancies, described elsewhere. 
19-26
The clinical benefit of duvelisib in RR and TN CLL is supported by the induction of durable disease responses. Lymphocytosis was observed in 70-75% of patients shortly after initiating duvelisib and, per recent guidance, 27 was not considered progressive disease. In RR CLL patients, ALC returned to baseline levels approximately 4 months into duvelisib treatment, which is shorter than reported for other BCR pathway inhibitors (BCRPIs) 28, 29 ORRs among all RR patients and the subset with TP53 mutation and/or 17p deletion, 56.4% and 46.4% respectively, were not dose dependent. While PFS appeared to differ between the RR CLL 25 mg BID and 75 mg BID cohorts, interpretation is limited by the phase 1 trial design and conduct, and further accentuated by the small patient numbers within each dose group.
Per eligibility criteria, TN CLL patients represented a population for which frontline chemoimmunotherapy would be considered suboptimal. The median age was 74, much older than in most frontline clinical trials of CLL. 30 Additionally, the proportion of patients with TP53 mutation and/or 17p deletion (56%) far exceeds the prevalence in the general untreated CLL population and typical frontline CLL therapy trials (5-10%). 30 Within this context, the ORR of 83% with 87% of responding patients maintaining response through 12 months is clinically meaningful.
Duvelisib was generally well tolerated in the RR CLL/SLL population, with some patients remaining on treatment for more than 3 years. The safety profile was consistent with the entire phase 1 patient population, 16 and characterized by potentially autoimmune toxicities similar to those observed with PI3K-δ inhibitor therapy. 31 While there were numerical differences in some individual AE incidences between the 25 mg BID and 75 mg BID dose cohorts, there did not appear to be a definitive dose effect of duvelisib on the overall safety profile in the RR CLL population. Diarrhea (47%) was the most frequently reported nonhematologic event but was managed with dose modifications and supportive-care interventions (eg, antidiarrheals) and rarely resulted in treatment discontinuation. In this report, the incidences of severe diarrhea (9.1%) and colitis (5.5%) are derived from the AE terms reported by investigators and in some cases these events overlapped. Colonoscopy data were not formally collected.
Transaminase elevations (25-27%) were mostly low-grade, reversible upon dosing interruptions, and rarely resulted in treatment discontinuation. Hematologic AEs, including grade 3 and 4 events, were also common but expected given baseline cytopenia (grade ≥ 3) in over a third of patients and not preclusive of maintaining therapy.
Infectious complications are a well-recognized major cause of morbidity and mortality in CLL, given the humoral immunodepression inherent to the disease and therapy-induced immunosuppression. 32, 33 Similar to other BCRPIs, infections, particularly pneumonias and URTIs, were frequently observed and remain an important risk. 34, 35 Fatal infections were reported in four patients, two of whom previously experienced disease progression. The requirement for prophylaxis added to this study was intended to mitigate the risk for
Pneumocystis pneumonia and continues to be implemented in duvelisib clinical trials.
The AE profile in TN was generally similar to RR, although incidences of diarrhea and transaminase elevations were higher. As noted previously, treatment with idelalisib and rituximab resulted in a high incidence of presumed immune-mediated side effects in patients with previously untreated CLL, and was higher in younger patients. 36, 37 The disruption of Treg signaling via PI3K-δ inhibition and the resultant emergence of a cytotoxic effector T-cell population may account for the autoimmune toxicities with the higher incidence in previously untreated and/or younger patients attributed to a better-preserved population of T cells. 37 While differences in study design and treatment exposure preclude direct cross-study comparisons of autoimmune toxicity risk, preclinical data support the rationale that concomitant inhibition of PI3K-γ by duvelisib may mitigate autoimmune complications through maintenance of a safe balance between regulatory and effector T-cell activity. It has been shown that inactivation of PI3K-γ, either through mutations or inhibition by small molecules, impairs the migration of leukocytes from the bloodstream to sites of injury or inflammation; in addition, PI3K-γ is required for optimal T-cell activation and differentiation. 38, 39 In mouse models of multiple chronic inflammatory diseases, PI3K-γ inhibition or absence abrogated disease activity. 38, [40] [41] [42] [43] [44] While the data from this small cohort suggest a predictable and manageable safety profile in TN patients, additional investigation to elucidate the pharmacologic and clinical sequelae of PI3K-γ inhibition by duvelisib would be informative.
Overall, the clinical and pharmacodynamic activity and manageable safety profile in these heavily pretreated, RR CLL/SLL, and high- 
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